Trial Site Detail
Drug: |
SF1126 |
|||
|---|---|---|---|---|
Trial: |
A Phase I Open Label, Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation Study in SF1126, a PI Kinase (PI3K) Inhibitor, Given Twice Weekly by IV Infusion to Patients With Advanced or Metastatic Tumors |
|||
| Conditions: | Solid Tumors | |||
Trial Status: |
Ongoing, but not recruiting |
|||
TGen Clinical Research Services10460 N. 92nd Street, Suite 206 |
Principal Investigator: |
Ramesh Ramanathan, MD |
|---|---|
Contact: |
Cathy Costanza, RN, BS, OCN 480-323-1550 ccostanza@shc.org Jennifer Privratsky 480-323-1591 jprivratsky@shc.org |
Activation Status of this Site: |
Closed |
Notes about this Site: |
|
TGen Clinical Research Services Website: |
http://www.tgen.org/research/index.cfm?pageid=1085 |
Navigating the Map
Use the plus (+) and minus (-) controls to zoom in/out.
Click and drag the map or use the arrows to move (pan) the map.
Tip: Click the marker before zooming and the map will stay centered on the marker as you zoom.